Moderna

Moderna is a publicly traded biotechnology company (NASDAQ: MRNA) that pioneered messenger-RNA (mRNA) medicines, reaching global scale with its COVID-19 vaccine and building a pipeline across infectious disease, oncology, and rare disease. It is included here not as an AI vendor but as one of the most-cited enterprise AI adopters in the life sciences: Moderna has deployed AI deeply across the business — reportedly 750-plus internal AI models, an organization-wide ChatGPT Enterprise rollout, and a partnership with OpenAI — to accelerate mRNA sequence design, optimize manufacturing, and run leaner operations.

The honest framing is the important part. Moderna does not sell an AI product; its value derives from its mRNA platform, pipeline, and manufacturing, with AI as an internal accelerant rather than a revenue line. That makes it a useful teaching example of the "AI adopter" pattern — how a science-and-manufacturing company uses AI as a horizontal productivity and R&D tool — and a contrast to the AI-native drug-discovery companies (such as Recursion or Insilico) whose core product is the AI platform itself. For learners, Moderna illustrates that the biggest near-term AI impact in many industries comes from adoption inside incumbents, not only from new AI-first entrants.